Bayer has received regulatory authorisation for Jessico Fusion, the first co-formulation of isoflucypram (Iblon) and fenpicoxamid (Inatreq). The news means Jessico Fusion will be available to growers for use across a range of winter and spring sown cereals in spring 2026.
“Jessico Fusion is the latest product to form part of the Iblon family of fungicides, all of which have demonstrated excellent efficacy against the principal foliar threats, such as septoria tritici, yellow rust and brown rust,” says fungicide market development Greg Hanna.
Bayer assessed Jessico Fusion’s activity across many seasons, which offered the opportunity to assess its performance under uniquely challenging conditions.
“In both the 2024 and 2025 seasons, when conditions were either extremely wet or exceptionally dry, Jessico Fusion performed impressively, frequently delivering the greatest yield uplift of any product in trial. This suggests the active substances in Jessico Fusion combine to deliver an excellent broad spectrum disease control solution well-suited to T2 but with the flexibility to be used at T1 in higher septoria pressure conditions.”
The prolonged dry weather of 2025 made assessing the disease control performance of all fungicides a challenge. “The 2025 season proved to be an extreme challenge but one that provided an opportunity to assess the physiological benefits of a fungicide. The extended chlorophyll activity seen with Iblon in earlier trials was repeated with Jessico Fusion with treated crops delivering a positive yield return in the absence of disease but under intense drought stress,” notes Greg.
Growers can apply a maximum of one application of Jessico Fusion per year up to a maximum individual dose of 1.5 L/ha.
